Loading today’s stories
Science2 distinct publishers3 min readPublished
After 14 years without a revision, US neurologists and headache specialists have folded CGRP-targeted drugs into the front rank of migraine prevention. That changes the first conversation in the clinic and the coverage fight behind it.
The Scientist · Science desk
Compiled by The ScientistSomething wrong?How this is made
Coverage of this update leans on one number: "up to 70 percent," which Science News gives as the share of people who get fewer migraines on CGRP-targeted drugs such as Aimovig and Ajovy [3]. That figure is a ceiling, not an average, and the source does not say how large a reduction counts or over what period. It also does not say which patients land at the top of that range.
The guideline leaves that unspecified too. CGRP levels rise during a migraine attack and fall once the attack has been treated or has resolved, which is what makes these drugs mechanism-based rather than repurposed from cardiology or epilepsy [19]. But the common form of migraine is not driven by a single mutation, Mayo Clinic neurologist Amaal Starling told Science News; it involves multiple genetic variants that build vulnerability [18]. No assay sorts responders from non-responders in advance, so selection still runs on delivery preference and comorbidity, with Starling's rule of thumb being the medication a patient will actually take [21]. The options include tablets, injections under the skin, and infusions into a vein [22]. STAT reports the recommendations are organised by which property you are prioritising, with separate tracks for patients who have a high body mass index, fibromyalgia or hypertension, or who might be pregnant [16].
That makes the reassessment window the operative clock. Three sequential attempts at eight to twelve weeks each occupy 24 to 36 weeks, roughly six to nine months of a patient's year, before anyone knows whether the third choice works [26]. For a sense of why the revision was overdue: at least six preventives won FDA approval after 2012 [5], which across the 14-year gap between guidelines is about one every 28 months [25].
The two population figures in these accounts are not the same denominator. Science News puts the group the guideline says should be offered prevention at roughly 8 million US adults [7]; STAT reports an estimated 15 percent of Americans experience migraine, with women disproportionately affected [9]. Neither publisher reconciles them, and the smaller figure is the one attached to the new eligibility language, where the older guidance had no explicit criteria at all [8]. Guideline co-author Rebecca Burch said population studies show many more patients with migraine are eligible than are being treated [27].
One conflict the guideline will not settle: its scientific review found the tricyclic amitriptyline a viable option for some pregnant patients, while the American College of Obstetricians and Gynecologists advises against tricyclics in pregnancy over the risk of major congenital abnormalities and other serious problems, according to STAT [17]. The guideline and ACOG disagree, and nothing in either document tells a clinician how to choose between them.
Migraine prevention now has drugs aimed at the disease, but the field still lacks a test aimed at the patient. What the update buys is clarity about whom to treat; the sequencing remains trial and error on an eight-to-twelve-week cycle.
Ranked by verification strength, evidence, and original report placement.
For the first time in 14 years, the American Academy of Neurology and the American Headache Society updated their guidelines for preventing migraine attacks, published August 31 in Neurology.
The guidance from the American Headache Society and the American Academy of Neurology was released Monday; the two groups last updated their recommendations in 2012.
Newer CGRP-targeting medications atogepant (Qulipta), eptinezumab (Vyepti), erenumab (Aimovig), fremanezumab (Ajovy) and galcanezumab (Emgality) received high marks for their efficacy and tolerability.
Among the key updates are at least a half dozen medications approved for migraine prevention by the FDA since 2012, many of them focused on blocking the CGRP pathway.
The new guidelines advise doctors to offer preventive treatment to people who have at least four migraine or severe headache days per month, or whose migraines interfere with their ability to work or complete daily tasks.
The group the guidelines say should be offered preventive treatment is roughly 8 million adults in the United States.
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 31, 2026
1 article · August 31, 2026
Follow any of these and your For You feed starts watching them — no settings page required.
product
A blood-draw robot clears the FDA at 1m49s a stick. The missing number is per supervisor1 distinct publisher
science
Coronary calcium earns one narrow job: breaking statin ties in the 3-to-10 percent band1 distinct publisher
science
Capricor's Duchenne vote is a verdict on design choices made years before the data1 distinct publisher
science
Focal prostate therapy is drifting outside the guideline that calls it experimental1 distinct publisher
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
One document, two readings
Everything here descends from a single peer-reviewed guideline in Neurology and a news briefing both outlets attended, which makes the core facts solid and the sourcing narrow. The strong parts are specific and checkable — the four-day threshold, the eight-to-12-week review, the named drugs. The soft parts are where a number travels without a study behind it, as with Science News' 'up to 70 percent,' and where the guideline's authors are asked to characterise their own work. STAT at least adds three outside experts, two of them named critics, and records that the neurology academy declined to comment.
Drugs in market, uptake unreported
The medicines are not speculative — at least six prevention approvals since 2012, five CGRP agents named with brand names, Botox and topiramate long in use. What nobody supplies is a prescription: not one figure on how many of the roughly 8 million newly eligible adults are on preventive therapy, or on how many prescriptions the CGRP class already carries. The strongest uptake signal in this reporting is an absence, Burch noting that population studies show far more patients qualify than are being treated, and payer prior authorization sitting between the recommendation and the pharmacy counter.
Mostly one unsourced number
'Game changer' and 'up to 70 percent' outrun what either outlet actually shows, and the framing of CGRP drugs as a paradigm shift comes largely from clinicians and a society position statement rather than from head-to-head data. But the overshoot is contained, because the same-day reporting carries its own brake: STAT documents a guideline complicated enough that a former society president expects primary care to avoid it, a cheap generic dismissed for insufficient evidence, a CGRP drug demoted, and a pregnancy recommendation at odds with obstetric guidance. Enthusiasm and skepticism are both on the page; the gap is the distance between them.
Branded stakes, partly disclosed
Five brand-name drugs being moved into the front rank of a 15%-prevalence condition is a large commercial event, and the actors in this story are not neutral: two professional societies are elevating a class one of them has already endorsed as first-line, and payers have an obvious interest in every qualification that permits refusal. Credit where it is due — STAT tells you Charles has consulted for several companies whose treatments appear in the guidance, and that he is the society's immediate past president. Science News does no equivalent for its interviewee, and neither outlet reports who funded the guideline process or what the authors disclosed.
Firm on the document, thin on effects
What the guideline says is about as settled as reporting gets: two outlets, same briefing, same journal, no factual disagreement between them. Confidence drops on consequences. Whether primary care adopts this, whether payers treat the qualifications as a ladder or a locked door, and how many of the 8 million eligible adults end up on treatment are all forecasts here, resting on one or two interested voices with no follow-up and no comment from the neurology academy.